Medicinova (MNOV) 3.81 $MNOV
MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia
GlobeNewswire - Mon Jul 27, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) has approved a second protocol for a clinical trial evaluating MN-001 (tipelukast) for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.
MNOV: 3.81 (+0.30)
MediciNova Announces Update on Development Plans for MN-001 in IPF
GlobeNewswire - Tue Jul 21, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is currently in late-stage discussions with investigators at Penn State University (principal investigator Dr. Rebecca Bascom) to conduct a Phase 2 study of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis).
MNOV: 3.81 (+0.30)
Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:30AM CDT
MNOV: 3.81 (+0.30), GLMD: 10.07 (-0.30), LJPC: 29.43 (+1.05), CNAT: 4.90 (-0.17), GALT: 2.63 (-0.06), RGLS: 8.68 (-0.49), DRRX: 2.49 (-0.10), RPTP: 13.77 (-0.72), GILD: 110.54 (-2.29), SHPG: 259.11 (+6.54), MRK: 56.99 (-0.42), AZN: 32.71 (-33.05), ICPT: 266.07 (-6.98), VBLT: 6.28 (-0.30), TBRA: 13.78 (-0.67)
MediciNova enrols 24 subjects under clinical trial of MN-166 (ibudilast) in alcohol dependence
M2 - Wed Jul 01, 3:44AM CDT
Biopharmaceutical company MediciNova (Nasdaq GM:MNOV) reported on Tuesday that it has completed enrollment in a clinical trial of 24 subjects in the study of MN-166 (ibudilast) in alcohol dependence.
MNOV: 3.81 (+0.30)
MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
GlobeNewswire - Tue Jun 30, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the clinical trial of MN-166 (ibudilast) in alcohol dependence has completed enrollment of 24 subjects.
MNOV: 3.81 (+0.30)
How To Make Money In Small To Nano-Cap Biotech
Scrying Biotech - at Seeking Alpha - Wed Jun 24, 12:55PM CDT
SGYP: 8.19 (+0.28), TRVN: 6.21 (-0.28), OCAT: 4.63 (-0.06), MNOV: 3.81 (+0.30), SGEN: 48.06 (-0.37), NVAX: 11.62 (-0.17), NKTR: 12.42 (-0.36)
MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting
GlobeNewswire - Wed Jun 24, 8:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that principal investigator Lara Ray, Ph.D., Associate Professor, Department of Psychology, Brain Research Institute at University of California Los Angeles, gave a RSA 2014 Young Investigator Awardee presentation today at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting in San Antonio, TX entitled "A RESEARCH AGENDA ON THE CLINICAL NEUROSCIENCE OF ALCOHOLISM." At the request of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the sponsor of the study, the presentation included preliminary interim data from the first 22 subjects in the ongoing clinical trial of MN-166 (ibudilast) in alcohol dependence. Dr. Ray commented "MN-166 (ibudilast) was very well tolerated and there were no drug-related drop outs or serious adverse events. The preliminary results indicate that ibudilast has beneficial effects on mood (p<0.05), decreased the daily measure of alcohol craving (p=0.05), and potentiated alcohol-induced sedation (p<0.05)."
MNOV: 3.81 (+0.30)
MediciNova Is An Excellent Opportunity In The Biotech Space
Emerging Equities - at Seeking Alpha - Mon Jun 22, 1:34PM CDT
MNOV: 3.81 (+0.30), IPF: 21.43 (-0.32)
MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology
GlobeNewswire - Tue Jun 16, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Addiction Biology has published a new article on MN-166 (ibudilast) entitled "The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers." The article was written by Ziva D. Cooper, Sandra D. Comer, and other colleagues at Columbia University and New York State Psychiatric Institute. The article discusses results of a clinical study which investigated the dose-dependent effects of MN-166 (ibudilast), a glial cell modulator, on withdrawal symptoms in opioid-dependent volunteers after abrupt discontinuation of morphine administration.
MNOV: 3.81 (+0.30)
MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
GlobeNewswire - Fri Jun 12, 4:59AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the ongoing clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) has completed randomization of 255 subjects, which exceeds the goal of 250 subjects that were planned for participation. NINDS (National Institute of Neurological Disorders and Stroke) is planning to conduct an interim efficacy analysis after half the subjects complete the 96-week treatment period, which analysis is expected to occur in the fall of 2016.
MNOV: 3.81 (+0.30)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 8:14AM CDT
PBMD: 1.28 (+0.03), MNOV: 3.81 (+0.30), SYN: 3.35 (+0.16), HALO: 22.80 (-0.44), SNCR: 43.72 (-2.68), ORIG: 3.89 (-0.19), CDTI: 1.71 (-0.01), GIII: 69.16 (-0.33), VRA: 10.75 (unch), VMEM: 2.06 (-0.01)
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
GlobeNewswire - Wed Jun 03, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-166 (ibudilast) for treatment of Krabbe disease. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Neurology Products (DNP) for MN-166 (ibudilast).
MNOV: 3.81 (+0.30)
Acucela names Shintaro Asako to board
M2 - Tue May 19, 4:39AM CDT
Acucela Inc (Tokyo:4589) , a clinical-stage biotechnology company specialising in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced on Tuesday that Shintaro Asako has been nominated to stand for election to the company's board of directors at the 2015 Annual Meeting of Shareholders on 25 June 2015.
MNOV: 3.81 (+0.30)
Seeking Alpha's Biotech Weekly: Celgene's Future, Northwest Bio's Science, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.19 (+0.06), NWBO: 10.99 (-0.87), MNOV: 3.81 (+0.30), ACT: 298.98 (-2.94), MDT: 75.66 (-0.35), OVAS: 30.03 (-0.61), AMRN: 2.16 (unch), XBI: 251.78 (-3.60), AERI: 18.55 (-0.07), IBB: 373.58 (-4.00), SPA: 23.63 (-0.09), NDRM: 18.79 (+0.44), GEVA: 238.60 (+2.80), QURE: 25.99 (-0.75), ACRX: 4.08 (-0.34), SSH: 3.02 (-0.09), VRTX: 123.23 (-2.27), GSK: 41.60 (+0.21), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34), GILD: 110.54 (-2.29), ALXN: 198.10 (-2.89), SCMP: 21.64 (-0.46), OHRP: 2.93 (-0.16), NVS: 101.54 (-0.26)
Ibudilast Phase 2 study fully enrolled; randomization to be completed in 4 - 6 weeks
Seeking Alpha - at Seeking Alpha - Thu May 07, 7:28AM CDT
MNOV: 3.81 (+0.30)
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
GlobeNewswire - Thu May 07, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has been notified by NINDS (National Institute of Neurological Disorders and Stroke) that the ongoing clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) is now fully enrolled. Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study. Randomization is expected to be completed in approximately 4 - 6 weeks.
MNOV: 3.81 (+0.30)
MediciNova's Deep Pipeline Is Meaningfully Undervalued
Jason Napodano, CFA - Seeking Alpha - Wed May 06, 2:57PM CDT
By Jason Napodano, CFA & David Bautz, PhD We are initiating coverage of MediciNova, Inc. (NASDAQ: MNOV ) with a Buy rating and an $8.00 price target. MediciNova is a biopharmaceutical company focused on developing small molecule therapeutics for...
MNOV: 3.81 (+0.30)
BUYINS.NET: ATVI, SHM, JXI, MNOV, ADK, BGS Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 29, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Activision Blizzard Inc (NASDAQ:ATVI), SPDR Nvn Barclys Cptl Shrt Trm Mncpl Bnd (NYSE:SHM), iShares S&P Global Utilities Sector Index Fund (NYSE:JXI), MediciNova Inc (NASDAQ:MNOV), ADCARE HEALTH SYSTEMS INC (NYSE:ADK), B&G Foods Inc (NYSE:BGS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ATVI: 25.61 (-0.57), MNOV: 3.81 (+0.30), JXI: 45.34 (+0.28), BGS: 28.99 (+0.01), SHM: 24.35 (+0.03), ADK: 3.79 (+0.06)
Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting
GlobeNewswire - Thu Apr 23, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Robert J. Fox from the Cleveland Clinic, principal investigator of MediciNova's ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS), made a presentation today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. The presentation included baseline characteristics for the first 228 subjects that were enrolled and randomized in the study as of April 6, 2015. A total of 250 subjects are planned for participation.
MNOV: 3.81 (+0.30)
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS
GlobeNewswire - Tue Apr 21, 12:45PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigator, presented interim safety data from the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. There were no safety or tolerability concerns in the MN-166 (ibudilast) treatment group compared with the placebo treatment group after three months of treatment.
MNOV: 3.81 (+0.30)
MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia
GlobeNewswire - Mon Jul 27, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) has approved a second protocol for a clinical trial evaluating MN-001 (tipelukast) for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.
MNOV: 3.81 (+0.30)
MediciNova Announces Update on Development Plans for MN-001 in IPF
GlobeNewswire - Tue Jul 21, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is currently in late-stage discussions with investigators at Penn State University (principal investigator Dr. Rebecca Bascom) to conduct a Phase 2 study of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis).
MNOV: 3.81 (+0.30)
Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:30AM CDT
MNOV: 3.81 (+0.30), GLMD: 10.07 (-0.30), LJPC: 29.43 (+1.05), CNAT: 4.90 (-0.17), GALT: 2.63 (-0.06), RGLS: 8.68 (-0.49), DRRX: 2.49 (-0.10), RPTP: 13.77 (-0.72), GILD: 110.54 (-2.29), SHPG: 259.11 (+6.54), MRK: 56.99 (-0.42), AZN: 32.71 (-33.05), ICPT: 266.07 (-6.98), VBLT: 6.28 (-0.30), TBRA: 13.78 (-0.67)
MediciNova enrols 24 subjects under clinical trial of MN-166 (ibudilast) in alcohol dependence
M2 - Wed Jul 01, 3:44AM CDT
Biopharmaceutical company MediciNova (Nasdaq GM:MNOV) reported on Tuesday that it has completed enrollment in a clinical trial of 24 subjects in the study of MN-166 (ibudilast) in alcohol dependence.
MNOV: 3.81 (+0.30)
MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
GlobeNewswire - Tue Jun 30, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the clinical trial of MN-166 (ibudilast) in alcohol dependence has completed enrollment of 24 subjects.
MNOV: 3.81 (+0.30)
How To Make Money In Small To Nano-Cap Biotech
Scrying Biotech - at Seeking Alpha - Wed Jun 24, 12:55PM CDT
SGYP: 8.19 (+0.28), TRVN: 6.21 (-0.28), OCAT: 4.63 (-0.06), MNOV: 3.81 (+0.30), SGEN: 48.06 (-0.37), NVAX: 11.62 (-0.17), NKTR: 12.42 (-0.36)
MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting
GlobeNewswire - Wed Jun 24, 8:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that principal investigator Lara Ray, Ph.D., Associate Professor, Department of Psychology, Brain Research Institute at University of California Los Angeles, gave a RSA 2014 Young Investigator Awardee presentation today at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting in San Antonio, TX entitled "A RESEARCH AGENDA ON THE CLINICAL NEUROSCIENCE OF ALCOHOLISM." At the request of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the sponsor of the study, the presentation included preliminary interim data from the first 22 subjects in the ongoing clinical trial of MN-166 (ibudilast) in alcohol dependence. Dr. Ray commented "MN-166 (ibudilast) was very well tolerated and there were no drug-related drop outs or serious adverse events. The preliminary results indicate that ibudilast has beneficial effects on mood (p<0.05), decreased the daily measure of alcohol craving (p=0.05), and potentiated alcohol-induced sedation (p<0.05)."
MNOV: 3.81 (+0.30)
MediciNova Is An Excellent Opportunity In The Biotech Space
Emerging Equities - at Seeking Alpha - Mon Jun 22, 1:34PM CDT
MNOV: 3.81 (+0.30), IPF: 21.43 (-0.32)
MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology
GlobeNewswire - Tue Jun 16, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Addiction Biology has published a new article on MN-166 (ibudilast) entitled "The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers." The article was written by Ziva D. Cooper, Sandra D. Comer, and other colleagues at Columbia University and New York State Psychiatric Institute. The article discusses results of a clinical study which investigated the dose-dependent effects of MN-166 (ibudilast), a glial cell modulator, on withdrawal symptoms in opioid-dependent volunteers after abrupt discontinuation of morphine administration.
MNOV: 3.81 (+0.30)
MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
GlobeNewswire - Fri Jun 12, 4:59AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the ongoing clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) has completed randomization of 255 subjects, which exceeds the goal of 250 subjects that were planned for participation. NINDS (National Institute of Neurological Disorders and Stroke) is planning to conduct an interim efficacy analysis after half the subjects complete the 96-week treatment period, which analysis is expected to occur in the fall of 2016.
MNOV: 3.81 (+0.30)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 8:14AM CDT
PBMD: 1.28 (+0.03), MNOV: 3.81 (+0.30), SYN: 3.35 (+0.16), HALO: 22.80 (-0.44), SNCR: 43.72 (-2.68), ORIG: 3.89 (-0.19), CDTI: 1.71 (-0.01), GIII: 69.16 (-0.33), VRA: 10.75 (unch), VMEM: 2.06 (-0.01)
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
GlobeNewswire - Wed Jun 03, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-166 (ibudilast) for treatment of Krabbe disease. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Neurology Products (DNP) for MN-166 (ibudilast).
MNOV: 3.81 (+0.30)
Acucela names Shintaro Asako to board
M2 - Tue May 19, 4:39AM CDT
Acucela Inc (Tokyo:4589) , a clinical-stage biotechnology company specialising in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced on Tuesday that Shintaro Asako has been nominated to stand for election to the company's board of directors at the 2015 Annual Meeting of Shareholders on 25 June 2015.
MNOV: 3.81 (+0.30)
Seeking Alpha's Biotech Weekly: Celgene's Future, Northwest Bio's Science, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.19 (+0.06), NWBO: 10.99 (-0.87), MNOV: 3.81 (+0.30), ACT: 298.98 (-2.94), MDT: 75.66 (-0.35), OVAS: 30.03 (-0.61), AMRN: 2.16 (unch), XBI: 251.78 (-3.60), AERI: 18.55 (-0.07), IBB: 373.58 (-4.00), SPA: 23.63 (-0.09), NDRM: 18.79 (+0.44), GEVA: 238.60 (+2.80), QURE: 25.99 (-0.75), ACRX: 4.08 (-0.34), SSH: 3.02 (-0.09), VRTX: 123.23 (-2.27), GSK: 41.60 (+0.21), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34), GILD: 110.54 (-2.29), ALXN: 198.10 (-2.89), SCMP: 21.64 (-0.46), OHRP: 2.93 (-0.16), NVS: 101.54 (-0.26)
Ibudilast Phase 2 study fully enrolled; randomization to be completed in 4 - 6 weeks
Seeking Alpha - at Seeking Alpha - Thu May 07, 7:28AM CDT
MNOV: 3.81 (+0.30)
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
GlobeNewswire - Thu May 07, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has been notified by NINDS (National Institute of Neurological Disorders and Stroke) that the ongoing clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) is now fully enrolled. Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study. Randomization is expected to be completed in approximately 4 - 6 weeks.
MNOV: 3.81 (+0.30)
MediciNova's Deep Pipeline Is Meaningfully Undervalued
Jason Napodano, CFA - Seeking Alpha - Wed May 06, 2:57PM CDT
By Jason Napodano, CFA & David Bautz, PhD We are initiating coverage of MediciNova, Inc. (NASDAQ: MNOV ) with a Buy rating and an $8.00 price target. MediciNova is a biopharmaceutical company focused on developing small molecule therapeutics for...
MNOV: 3.81 (+0.30)
BUYINS.NET: ATVI, SHM, JXI, MNOV, ADK, BGS Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 29, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Activision Blizzard Inc (NASDAQ:ATVI), SPDR Nvn Barclys Cptl Shrt Trm Mncpl Bnd (NYSE:SHM), iShares S&P Global Utilities Sector Index Fund (NYSE:JXI), MediciNova Inc (NASDAQ:MNOV), ADCARE HEALTH SYSTEMS INC (NYSE:ADK), B&G Foods Inc (NYSE:BGS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ATVI: 25.61 (-0.57), MNOV: 3.81 (+0.30), JXI: 45.34 (+0.28), BGS: 28.99 (+0.01), SHM: 24.35 (+0.03), ADK: 3.79 (+0.06)
Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting
GlobeNewswire - Thu Apr 23, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Robert J. Fox from the Cleveland Clinic, principal investigator of MediciNova's ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS), made a presentation today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. The presentation included baseline characteristics for the first 228 subjects that were enrolled and randomized in the study as of April 6, 2015. A total of 250 subjects are planned for participation.
MNOV: 3.81 (+0.30)
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS
GlobeNewswire - Tue Apr 21, 12:45PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigator, presented interim safety data from the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. There were no safety or tolerability concerns in the MN-166 (ibudilast) treatment group compared with the placebo treatment group after three months of treatment.
MNOV: 3.81 (+0.30)
